Atrium Therapeutics, Inc. Research and Development Expense
Atrium Therapeutics, Inc. (RNA) reported Research and Development Expense of $15.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Atrium Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $15.34M, a 15.42% increase year-over-year.
- Atrium Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $16.66M, a 140.12% increase year-over-year.
- Atrium Therapeutics, Inc. research and development expense for the quarter ending 2025-06-30 was $13.29M.
- Atrium Therapeutics, Inc. research and development expense for the quarter ending 2025-03-31 was $6.94M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month |
|---|---|---|
| 2026-06-30 | $15.34M 10-Q · filed 2026-08-13 | $32.00M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $16.66M 10-Q · filed 2026-05-14 | |
| 2025-06-30 | $13.29M 10-Q · filed 2026-08-13 | $20.23M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $6.94M 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |